NO20060654L - PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme - Google Patents
PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende sammeInfo
- Publication number
- NO20060654L NO20060654L NO20060654A NO20060654A NO20060654L NO 20060654 L NO20060654 L NO 20060654L NO 20060654 A NO20060654 A NO 20060654A NO 20060654 A NO20060654 A NO 20060654A NO 20060654 L NO20060654 L NO 20060654L
- Authority
- NO
- Norway
- Prior art keywords
- same
- group
- pharmaceutical composition
- composition containing
- activating compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Det er beskrevet en forbindelse for selektiv aktivering av PPARa som er representert ved den generelle formel (1) (hvor R, og R2, som kan være like eller forskjellige, representerer et hydrogenatom eller lignende; R3a, R3b, R4a og R4b, kan være like eller forskjellige, og representerer et hydrogenatom eller lignende; X representerer et oksygenatom eller lignende; Y representerer et oksygenatom, S(O)i (I er tallene 0 til 2), en karbonylgruppe, en karbonylaminogruppe, en aminokarbonylgruppe, en sulfonylaminogruppe eller en NH-gruppe; Z representerer CH eller lignende; n er tallene 1 til 6; og m er tallene 2 til 6) eller et salt derav. Det er også beskrevet et terapeutisk medikament inneholdende en slik forbindelse.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49935703P | 2003-09-03 | 2003-09-03 | |
| JP2003317353 | 2003-09-09 | ||
| JP2003364817 | 2003-10-24 | ||
| PCT/JP2004/012750 WO2005023777A1 (ja) | 2003-09-03 | 2004-09-02 | Ppar活性化化合物及びこれを含有する医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20060654L true NO20060654L (no) | 2006-04-26 |
| NO335823B1 NO335823B1 (no) | 2015-02-23 |
Family
ID=34279568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060654A NO335823B1 (no) | 2003-09-03 | 2006-02-09 | PPAR-aktiverende forbindelse samt anvendelse derav, og terapeutisk medikament inneholdende samme |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7109226B2 (no) |
| EP (1) | EP1661890B1 (no) |
| JP (2) | JP4226005B2 (no) |
| KR (1) | KR101160808B1 (no) |
| AU (1) | AU2004270538C1 (no) |
| BR (1) | BRPI0413991B8 (no) |
| CA (1) | CA2535749C (no) |
| CY (1) | CY1111867T1 (no) |
| EA (1) | EA009374B1 (no) |
| HK (1) | HK1093975A1 (no) |
| HR (1) | HRP20110009T1 (no) |
| IL (1) | IL173639A (no) |
| MX (1) | MXPA06002435A (no) |
| NO (1) | NO335823B1 (no) |
| NZ (1) | NZ545692A (no) |
| PL (1) | PL1661890T3 (no) |
| TW (1) | TWI324599B (no) |
| WO (1) | WO2005023777A1 (no) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2338789T3 (es) | 2003-06-18 | 2010-05-12 | Tranzyme Pharma Inc. | Antagonistas macrociclicos del receptor de motilina. |
| EP1648922B9 (en) * | 2003-07-31 | 2013-04-03 | Tranzyme Pharma Inc. | Spatially-defined macrocyclic compounds useful for drug discovery |
| US7398116B2 (en) | 2003-08-11 | 2008-07-08 | Veran Medical Technologies, Inc. | Methods, apparatuses, and systems useful in conducting image guided interventions |
| US7301033B2 (en) * | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
| PL1852426T3 (pl) | 2005-02-23 | 2014-04-30 | Kowa Co | Sposób wytwarzania optycznie czynnego związku aktywującego PPAR oraz związku pośredniego |
| EP1854779A4 (en) * | 2005-03-01 | 2010-07-21 | Kowa Co | OPTICALLY ACTIVE, PPAR-ACTIVATING COMPOSITE INTERMEDIATE PRODUCT AND MANUFACTURING METHOD THEREFOR |
| ES2342319T3 (es) * | 2005-05-31 | 2010-07-05 | Kowa Co., Ltd. | Procedimiento para la produccion de compuestos para activar ppar opticamente activos. |
| EP1908747B1 (en) | 2005-07-28 | 2012-01-04 | Kowa Company, Ltd. | Process for producing optically active 2-hydroxybutyric ester |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| WO2008094860A2 (en) * | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| EP2484361B1 (en) * | 2009-09-28 | 2015-11-11 | Kowa Company, Ltd. | Agent for reducing visceral fat weight |
| TWI425948B (zh) * | 2012-01-20 | 2014-02-11 | Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases | |
| CA2901650C (en) * | 2012-09-27 | 2021-05-04 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
| EP2980061A4 (en) | 2013-03-29 | 2016-09-07 | Kowa Co | PROCESS FOR IMPROVING THE OPTICAL PURITY OF 2-HYDROXYCARBOXYLIC ACID OR ITS DERIVATIVE |
| TWI696462B (zh) | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| AU2014312931B2 (en) | 2013-08-28 | 2019-09-19 | Kowa Company, Ltd. | Therapeutic agent for dyslipidemia |
| AU2015204572B2 (en) * | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| TW201618777A (zh) * | 2014-09-26 | 2016-06-01 | 興和股份有限公司 | 脂質異常症治療劑 |
| WO2017082393A1 (ja) * | 2015-11-12 | 2017-05-18 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| PT3275438T (pt) | 2016-07-29 | 2021-01-25 | Kowa Co | Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual |
| US20210069157A1 (en) * | 2016-08-25 | 2021-03-11 | Kowa Company, Ltd. | Agent for treatment of pbc |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| CN110167595A (zh) | 2017-01-11 | 2019-08-23 | 兴和株式会社 | 非酒精性脂肪性肝病的预防及治疗药 |
| US10314825B2 (en) | 2017-02-24 | 2019-06-11 | Kowa Company, Ltd. | Agent for treatment of PBC |
| EP3646865A4 (en) | 2017-06-30 | 2021-03-17 | Kowa Company, Ltd. | MEDICINE |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| US20200121648A1 (en) * | 2017-06-30 | 2020-04-23 | Kowa Company, Ltd. | Pharmaceutical composition |
| EP3646866A4 (en) * | 2017-06-30 | 2021-03-24 | Kowa Company, Ltd. | PHARMACEUTICAL PREPARATION |
| WO2019004447A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| EP3646863B1 (en) * | 2017-06-30 | 2024-01-03 | Kowa Company, Ltd. | Pharmaceutical composition |
| US11419854B2 (en) | 2017-06-30 | 2022-08-23 | Kowa Company, Ltd. | Medicament containing pemafibrate |
| EP3646867A4 (en) | 2017-06-30 | 2021-03-24 | Kowa Company, Ltd. | PHARMACEUTICAL COMPOSITION |
| JPWO2019004452A1 (ja) * | 2017-06-30 | 2020-04-30 | 興和株式会社 | 医薬組成物 |
| WO2019004451A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| CN111741753A (zh) * | 2017-12-21 | 2020-10-02 | 兴和株式会社 | 治疗高甘油三酯血症的方法 |
| WO2019133462A1 (en) | 2017-12-27 | 2019-07-04 | Teva Pharmaceuticals International Gmbh | Solid state forms of pemafibrate |
| US20210290598A1 (en) | 2018-05-08 | 2021-09-23 | National University Corporation Okayama University | Medicament useful for cardiovascular disease |
| JP7071538B2 (ja) | 2018-12-27 | 2022-05-19 | 興和株式会社 | 医薬組成物 |
| EP3903780A4 (en) * | 2018-12-27 | 2023-01-18 | Kowa Company, Ltd. | MEDICINAL PRODUCT |
| TW202038906A (zh) | 2018-12-27 | 2020-11-01 | 日商興和股份有限公司 | 醫藥品 |
| WO2021119397A1 (en) | 2019-12-13 | 2021-06-17 | Rgenix, Inc. | Metal salts and uses thereof |
| US20240197688A1 (en) | 2021-04-20 | 2024-06-20 | Kowa Company, Ltd. | Combination medicine for preventing/treating dyslipidemia or cardiovascular disease |
| CA3216699A1 (en) | 2021-04-28 | 2022-11-03 | Kowa Company, Ltd. | Blood carnitine-increasing agent |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6025425B2 (ja) * | 1975-03-06 | 1985-06-18 | 藤沢薬品工業株式会社 | 置換フエノキシ脂肪酸類の合成法 |
| JPS593465B2 (ja) * | 1974-06-04 | 1984-01-24 | 藤沢薬品工業株式会社 | チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| JPWO2002046176A1 (ja) * | 2000-12-05 | 2004-04-08 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体の活性化剤 |
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| EP1480957A1 (en) * | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
-
2004
- 2004-09-02 AU AU2004270538A patent/AU2004270538C1/en not_active Ceased
- 2004-09-02 CA CA2535749A patent/CA2535749C/en not_active Expired - Fee Related
- 2004-09-02 MX MXPA06002435A patent/MXPA06002435A/es active IP Right Grant
- 2004-09-02 BR BRPI0413991A patent/BRPI0413991B8/pt not_active IP Right Cessation
- 2004-09-02 JP JP2005513668A patent/JP4226005B2/ja active Active
- 2004-09-02 PL PL04772699T patent/PL1661890T3/pl unknown
- 2004-09-02 EP EP04772699A patent/EP1661890B1/en active Active
- 2004-09-02 KR KR1020067003950A patent/KR101160808B1/ko active IP Right Grant
- 2004-09-02 WO PCT/JP2004/012750 patent/WO2005023777A1/ja active Application Filing
- 2004-09-02 NZ NZ545692A patent/NZ545692A/xx unknown
- 2004-09-02 EA EA200600527A patent/EA009374B1/ru not_active IP Right Cessation
- 2004-09-03 US US10/933,467 patent/US7109226B2/en active Active
- 2004-09-03 TW TW093126702A patent/TWI324599B/zh not_active IP Right Cessation
-
2006
- 2006-02-09 NO NO20060654A patent/NO335823B1/no not_active IP Right Cessation
- 2006-02-09 IL IL173639A patent/IL173639A/en active IP Right Grant
- 2006-04-20 US US11/407,076 patent/US7183295B2/en active Active
- 2006-12-29 HK HK06114278.8A patent/HK1093975A1/xx not_active IP Right Cessation
-
2008
- 2008-10-31 JP JP2008281020A patent/JP4931893B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-07 HR HR20110009T patent/HRP20110009T1/hr unknown
- 2011-03-31 CY CY20111100343T patent/CY1111867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060654L (no) | PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme | |
| BG108089A (en) | Pyridine matrix metalloproteinase inhibitors | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| DK1246806T3 (da) | Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin | |
| NO20083026L (no) | Terapeutisk middel for diabetes | |
| NO20045369L (no) | Nye, substituerte sulfamatanticonvulsivaderivater | |
| EA200600620A1 (ru) | Набор для ингаляции с ингаляционным порошком, содержащим тиотропий | |
| HUP0303317A2 (hu) | Orto, meta-szubsztituált biszarilszármazékok, eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| TNSN06442A1 (en) | Chemical compounds | |
| NO20051695L (no) | Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer | |
| MX2008000255A (es) | Activadores de urea glucocinasa. | |
| NO20052609L (no) | Granulert kobber (I) oksid for anvendelse i begroingshindrerende belegg | |
| NO20070570L (no) | Forbindelser. | |
| NO20011351L (no) | Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav | |
| DK1483246T3 (da) | 5-Substituerede alkylaminopyrazolderivater som pesticider | |
| WO2002092072A3 (en) | Drugs for the treatment of the alzheimer disease | |
| AU2003294082A1 (en) | Composition comprising a carbamic acid derivative, its use as cosmetic and medicine | |
| DE602004029355D1 (de) | Sulfopyrrolderivate | |
| NO20083790L (no) | Nye terapeutiske kombinasjoner for behandling eller forebygging av psykotiske lidelser | |
| HUP0402038A2 (hu) | 2-Amino-4-heteroaril-etil-tiazolin-származékok alkalmazása az indukálható NO-szintetáz inhibitoraként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE60227421D1 (de) | Rmazeutische zusammensetzung und verwendung davon | |
| SE0200198D0 (sv) | New use | |
| BRPI0406840A (pt) | Derivados de acil-fenil-uréia substituìdos por carbonilamino, processos para a sua preparação e sua aplicação | |
| BRPI0409951A (pt) | derivados de anilina, sua produção e uso como agentes farmacêuticos | |
| NO20050834L (no) | Ny indolinforbindelse og medisinsk anvendelse derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |